NewsBenzingaOppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40 Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40 Benzinga 2026.09.22 17:10 (GMT+0) Open on Benzinga Other news Meta admits Muse’s likeness to OpenClaw isn’t a coincidence Dear Microsoft Stock Fans, Mark Your Calendars for September 24 This High-Growth Energy Stock Continues to Plunge. Don’t Rush to Buy the Dip. a16z is challenging Silicon Valley’s love for drop-outs by launching a school Arm Stock: Too Good to Sell, Too Expensive to Buy 'Royal Caribbean nears deal for Sandals valuing resorts at more than $6bn' - Financial Times
